ANAB Anaptysbio, Inc - 8-K

Item 7.01 Regulation FD Disclosure.

AnaptysBio, Inc. (the “Company”) has filed Form 8937 with the IRS and will also post Form 8937 information under the “Investors” section of its website at www.anaptysbio.com. The Form 8937 provides information about the dividend received by stockholders resulting from the separation and spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks”) from the Company. The Form 8937 also provides guidance on how the dividend is treated by the Company’s stockholders and how the change in tax basis is determined.

The Company’s stockholders are urged to consult their own tax advisor as to the particular tax consequences of the distribution of the First Tracks common stock, including potential tax consequences under state, local and non-U.S. tax laws. The Company is providing the details on the Form 8937 for informational purposes only and is not to be considered or construed as legal or tax advice.

The information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.